Sai Life Sciences Secures FDA EIRs

Sai Life Sciences, a fast-growing Indian Contract Research, Development, and Manufacturing Organization (CRDMO), has received Establishment Inspection Reports (EIRs) from the U.S. FDA for its R&D and manufacturing facilities in India. These EIRs follow successful audits of its R&D site in Hyderabad and manufacturing site in Bidar, confirming that both facilities meet the FDA’s Good Manufacturing Practices (GMP) standards. The Hyderabad facility underwent a GMP audit in April 2024, while the Bidar manufacturing unit was inspected for pre-approval and GMP compliance in June 2024.

CEO Krishna Kanumuri highlighted that these positive audit outcomes showcase Sai Life Sciences’ dedication to quality and compliance in its global operations. By achieving FDA recognition, Sai Life Sciences reinforces its capability to produce high-quality pharmaceutical products that meet international standards. The company is positioned to reliably support the supply chains of global pharmaceutical markets with its established quality frameworks and processes.

The success of these audits not only strengthens Sai Life Sciences' reputation but also demonstrates its commitment to regulatory excellence, setting the stage for continued growth as it expands its footprint in contract research and manufacturing worldwide.